Clinical Trial: Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07816289) titled 'Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)' on Sept. 07.

Brief Summary: This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).

Study Start Date: Oct. 15

Study Type: INTERVENTIONAL

Condition: Wet Age-related Macular Degeneration

Intervention: DRUG: OLN324

OLN324 by intravitreal injection monthly

DRUG: Ranibizumab

Ranibizumab by intravitreal injection monthly

Recruitment Status: NOT_YET_RECRUITING...